• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by OmniAb Inc.

    4/7/25 8:00:33 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $OABI alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001237556
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    OmniAb, Inc.
    SEC File Number
    001-40720
    Address of Issuer
    5980 HORTON STREET
    SUITE 600
    EMERYVILLE
    CALIFORNIA
    94608
    Phone
    510-250-7800
    Name of Person for Whose Account the Securities are To Be Sold
    FOEHR MATTHEW W
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    COMMON
    MORGAN STANLEY SMITH BARNEY LLC EXECUTIVE SERVICES
    200 W CIVIC CENTER DR. 4TH FLOOR
    SANDY � UT � 84070
    1938238714.7912213494104/07/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    COMMON04/07/2025RESTRICTED STOCKISSUERCheckbox not checked3645804/07/2025COMPENSATION

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Matthew W Foehr
    5980 HORTON STREET SUITE 600
    EMERYVILLE � CA � 94608
    COMMON01/21/202541811135377.56
    Matthew W Foehr
    5980 HORTON STREET SUITE 600
    Emeryville � CA � 94608
    COMMON02/18/20251396451390.16
    Matthew W Foehr
    5980 HORTON STREET SUITE 600
    Emeryville � CA � 94608
    COMMON02/19/20251952271646.01

    144: Remarks and Signature

    Remarks
    Represents the number of shares expected to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a sell-to-cover transaction and do not represent discretionary trades by the reporting person.
    Date of Notice
    04/07/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Charles S. Berkman, as Attorney-In-Fact for Matthew W. Foehr

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $OABI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OABI

    DatePrice TargetRatingAnalyst
    11/29/2023$6.00Outperform
    RBC Capital Mkts
    4/21/2023$8.00Buy
    The Benchmark Company
    4/13/2023$10.00Buy
    Craig Hallum
    2/22/2023$10.00Outperform
    Cowen
    2/13/2023$11.00Buy
    H.C. Wainwright
    More analyst ratings

    $OABI
    Leadership Updates

    Live Leadership Updates

    See more
    • OmniAb Appoints Steve Love to its Board of Directors

      OmniAb, Inc. (NASDAQ:OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb's Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors. "We are delighted Steve has agreed to join the OmniAb Board of Directors and extend a warm welcome," stated John Higgins, OmniAb Board Chair. "Steve's vast financial expertise, technical knowledge and experience leading technology and biotechnology companies will be valuable assets as we grow and expand our

      11/1/23 9:00:00 AM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cochran Jennifer R. bought $45,600 worth of shares (30,000 units at $1.52), increasing direct ownership by 26% to 145,274 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/15/25 4:02:17 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Love Steven bought $36,500 worth of shares (25,000 units at $1.46), increasing direct ownership by 188% to 38,333 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/14/25 5:04:09 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Higgins John L bought $93,600 worth of shares (65,000 units at $1.44), increasing direct ownership by 2% to 2,831,887 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/13/25 5:52:02 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital Mkts initiated coverage on OmniAb with a new price target

      RBC Capital Mkts initiated coverage of OmniAb with a rating of Outperform and set a new price target of $6.00

      11/29/23 7:31:15 AM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • The Benchmark Company initiated coverage on OmniAb with a new price target

      The Benchmark Company initiated coverage of OmniAb with a rating of Buy and set a new price target of $8.00

      4/21/23 7:43:22 AM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Craig Hallum initiated coverage on OmniAb with a new price target

      Craig Hallum initiated coverage of OmniAb with a rating of Buy and set a new price target of $10.00

      4/13/23 9:08:06 AM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $OABI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • OmniAb Reports First Quarter 2025 Financial Results and Business Highlights

      Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates. "We have started the year with robust deal flow, including both platform and asset-based deals. Our business remains strong as our diversified pipeline of partner programs is progressing with recent and expected new clinical entrants and data readouts," said Matt Foehr, Chief Executive Officer of OmniAb. "Today we announced the xPloration® Partner Access Program for OmniAb partners, enhancing the scalability of our technology platforms and creating new business opportuni

      5/8/25 4:06:00 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • OmniAb Introduces the xPloration® Partner Access Program

      High-Throughput Single B-Cell Screening Platform Now Available for Purchase by OmniAb's Partners for Use in Their Own Laboratories OmniAb, Inc. (NASDAQ:OABI) today introduced the launch of the xPloration Partner Access Program, under which current OmniAb partners can purchase the xPloration instrument to significantly enhance their capabilities in antibody discovery and development. xPloration is OmniAb's proprietary, innovative, high-throughput single B-cell screening platform that leverages machine learning and artificial intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508776052/en/ "xPloration has been a core

      5/8/25 4:05:00 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

      ZURICH, SWITZERLAND, May 5, 2025 -- VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager")), announced today a co-discovery alliance with OmniAb, Inc. (NASDAQ:OABI, "OmniAb")) for the development of a novel bispecific antibody drug conjugate ("bsADC") program targeting solid tumors. The collaboration brings together OmniAb's suite of transgenic antibody discovery solutions with VERAXA's proprietary antibody drug conjugate ("ADC") linker technology and conjugation expertise to support next-generation therapeutic discovery. "This partnership brings together two highly co

      5/5/25 1:00:00 AM ET
      $OABI
      $VACH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13G/A filed by OmniAb Inc.

      SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

      11/14/24 4:06:53 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13D/A filed by OmniAb Inc.

      SC 13D/A - OmniAb, Inc. (0001846253) (Subject)

      7/2/24 5:00:16 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cochran Jennifer R. bought $45,600 worth of shares (30,000 units at $1.52), increasing direct ownership by 26% to 145,274 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/15/25 4:02:17 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Love Steven bought $36,500 worth of shares (25,000 units at $1.46), increasing direct ownership by 188% to 38,333 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/14/25 5:04:09 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Higgins John L bought $93,600 worth of shares (65,000 units at $1.44), increasing direct ownership by 2% to 2,831,887 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      5/13/25 5:52:02 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by OmniAb Inc.

      SCHEDULE 13G/A - OmniAb, Inc. (0001846253) (Subject)

      5/14/25 12:32:07 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 10-Q filed by OmniAb Inc.

      10-Q - OmniAb, Inc. (0001846253) (Filer)

      5/8/25 4:51:53 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • OmniAb Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OmniAb, Inc. (0001846253) (Filer)

      5/8/25 4:11:02 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $OABI
    Financials

    Live finance-specific insights

    See more
    • OmniAb Reports First Quarter 2025 Financial Results and Business Highlights

      Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates. "We have started the year with robust deal flow, including both platform and asset-based deals. Our business remains strong as our diversified pipeline of partner programs is progressing with recent and expected new clinical entrants and data readouts," said Matt Foehr, Chief Executive Officer of OmniAb. "Today we announced the xPloration® Partner Access Program for OmniAb partners, enhancing the scalability of our technology platforms and creating new business opportuni

      5/8/25 4:06:00 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • OmniAb to Report First Quarter 2025 Financial Results on May 8

      OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Thursday, May 8, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss first quarter 2025 financial results and business updates       Date:   Thursday, May 8, 2025       Time:   4:30 p.m. Eastern time (1:30 p.m. Pacific time)       Phone:   U.S. (800) 549 8228     International (289) 819 1520     Conference ID is 96760    

      4/14/25 8:00:00 AM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

      Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates. "2024 was a remarkable year featuring double-digit percentage growth in the number of both active partners and programs. Clinical-stage programs advanced well, and we launched new technologies and enhancements that strengthened our platform and expanded our reach," said Matt Foehr, Chief Executive Officer of OmniAb. "We exceeded our internal goals for key metrics and continued to build momentum while optimizing the scalability of our business. We believe our co

      3/18/25 4:05:00 PM ET
      $OABI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care